174 related articles for article (PubMed ID: 8514401)
21. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.
Kozel TR; Weinhold LC; Lupan DM
Infect Immun; 1996 Aug; 64(8):3360-8. PubMed ID: 8757876
[TBL] [Abstract][Full Text] [Related]
22. Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells.
Kozel TR; Tabuni A; Young BJ; Levitz SM
Infect Immun; 1996 Jun; 64(6):2336-8. PubMed ID: 8675346
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
24. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
Kozel TR; Gotschlich EC
J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
[TBL] [Abstract][Full Text] [Related]
25. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
Laxalt KA; Kozel TR
Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
[TBL] [Abstract][Full Text] [Related]
26. Activation of the complement system by the capsule of Cryptococcus neoformans.
Kozel TR
Curr Top Med Mycol; 1993; 5():1-26. PubMed ID: 8242797
[TBL] [Abstract][Full Text] [Related]
27. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
28. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
29. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
MacGill TC; MacGill RS; Kozel TR
Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
[TBL] [Abstract][Full Text] [Related]
30. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils.
Kozel TR; Highison B; Stratton CJ
Infect Immun; 1984 Feb; 43(2):574-9. PubMed ID: 6363293
[TBL] [Abstract][Full Text] [Related]
31. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.
Cherniak R; Morris LC; Belay T; Spitzer ED; Casadevall A
Infect Immun; 1995 May; 63(5):1899-905. PubMed ID: 7729900
[TBL] [Abstract][Full Text] [Related]
32. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.
Small JM; Mitchell TG
Infect Immun; 1989 Dec; 57(12):3751-6. PubMed ID: 2680980
[TBL] [Abstract][Full Text] [Related]
33. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
34. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide.
Dromer F; Gueho E; Ronin O; Dupont B
J Clin Microbiol; 1993 Feb; 31(2):359-63. PubMed ID: 8432823
[TBL] [Abstract][Full Text] [Related]
35. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
Kozel TR; Follette JL
Infect Immun; 1981 Mar; 31(3):978-84. PubMed ID: 7014468
[TBL] [Abstract][Full Text] [Related]
36. Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.
Ikeda R; Nishikawa A; Shinoda T; Fukazawa Y
Microbiol Immunol; 1985; 29(10):981-91. PubMed ID: 3908888
[TBL] [Abstract][Full Text] [Related]
37. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
38. Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.
Small JM; Mitchell TG
Infect Immun; 1986 Dec; 54(3):742-50. PubMed ID: 3536747
[TBL] [Abstract][Full Text] [Related]
39. Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.
Pirofski LA
Infect Immun; 2006 Jun; 74(6):3079-84. PubMed ID: 16714535
[No Abstract] [Full Text] [Related]
40. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis.
Holzer TJ; Edwards KM; Gewurz H; Mold C
J Immunol; 1984 Sep; 133(3):1424-30. PubMed ID: 6747291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
